Previous Close | 7.14 |
Open | 7.15 |
Bid | 2.98 x 1200 |
Ask | 9.50 x 1000 |
Day's Range | 7.06 - 7.65 |
52 Week Range | 5.17 - 15.86 |
Volume | |
Avg. Volume | 122,796 |
Market Cap | 323.286M |
Beta (5Y Monthly) | -0.15 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.27 |
Earnings Date | Mar 27, 2023 - Mar 31, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 30.14 |
Subscribe to Yahoo Finance Plus to view Fair Value for KNTE
SAN FRANCISCO and SAN DIEGO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its board of directors has appointed a new independent director, Jill DeSimone, who will join effective March 1, 2023. Ms. DeSimone brings more than forty years of global business expertise in life sciences to Kinnate’s board of directors. Dean J. Mitchell, chairman of the Kinnate board of directors, commented, “I am h
SAN FRANCISCO and SAN DIEGO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced the poster presentation of the design and rationale of a Phase 1 trial-in-progress (KN-4802, NCT05242822) evaluating the Company’s investigational pan-FGFR inhibitor, KIN-3248, at two upcoming American Society of Clinical Oncology (ASCO)-related conferences. KIN-3248 is an irreversible, small molecule pan-FGFR inhibitor des
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...